Publications by authors named "June Xu"

Claim this Profile
A
A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.
Pingli Wang, Liming Cao, Panwen Tian, Shengxiang Ren, Liyun Miao, June Xu

Cancer Commun (Lond)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action.
Seunghun P Lee, Jenson Qi, Guozhang Xu, Matthew M Rankin, James Littrell, June Zhi Xu

Front Endocrinol (Lausanne)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer.
Hui Qi, Anwen Xiong, Lei Jiang, Hardy Van, June Xu

Transl Lung Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
Guozhang Xu, Michael D Gaul, Zhijie Liu, Renee L DesJarlais, Jenson Qi, Weixue Wang, June Zhi Xu

Bioorg Med Chem Lett· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.
Guozhang Xu, Fuyong Du, Gee-Hong Kuo, June Zhi Xu, Yin Liang

Bioorg Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.
Guozhang Xu, Michael D Gaul, Gee-Hong Kuo, Fuyong Du, June Zhi Xu

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors.
Gee-Hong Kuo, Micheal D Gaul, Yin Liang, June Z Xu, Fuyong Du, Guozhang Xu

Bioorg Med Chem Lett· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel potent GPR40 full agonist.
Sanath K Meegalla, Hui Huang, Tonya Martin, June Xu, Shuyuan Zhao

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Yin Liang, Kenji Arakawa, Kiichiro Ueta, Yasuaki Matsushita, Chiaki Kuriyama, June Xu

PLoS One· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
Lan Shen, Yan Zhang, Aihua Wang, Ellen Sieber-McMaster, Xiaoli Chen, June Z Xu

Bioorg Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.
Jay M Matthews, Xiaoli Chen, Ellen Cryan, Dennis J Hlasta, Philip J Rybczynski, June Z Xu

Bioorg Med Chem Lett· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis